1 – 35 of 35
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
- 2019
-
Mark
Det första steget för ett svenskt njurbytesprogram
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Living Anonymous Renal Donors Do Not Regret : Intermediate and Long-Term Follow-Up with a Focus on Motives and Psychosocial Outcomes
(
- Contribution to journal › Article
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
- 2017
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
- 2016
-
Mark
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and Comorbidity Over 10 Years in Elderly Women.
(
- Contribution to journal › Article
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
The long-term outcomes of systemic vasculitis.
(
- Contribution to journal › Scientific review
-
Mark
NT-rådets ställningstagande till eculizumab är oacceptabelt
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Slutreplik, Diana Karpman och medförfattare : - NT-rådet bör omedelbart återkalla sitt beslut om eculizumab
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
- 2013
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
- 2010
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
- 2009
-
Mark
The association between relapses of ANCA-associated vasculitis and the composite endpoint of end-stage renal disease or death
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictors of long-term (>= 5 year) renal survival in 535 patients with ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term survival of ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
(
- Contribution to journal › Article
-
Mark
Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin
(
- Contribution to journal › Published meeting abstract
-
Mark
Optimizing the Birmingham vasculitis activity scale to predict end-stage renal disease and death in ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial
(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Randomized trial of plasma exchange or high-dosage Methylprednisolone as adjunctive therapy for severe renal vasculitis
(
- Contribution to journal › Article
-
Mark
Sjukdomar i njurar och urinvägar
2007) p.303-303(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
På väg mot evidensbaserad terapi vid primär systemisk vaskulit. De senaste decenniernas framsteg har gett dagens patienter bättre läge
(
- Contribution to journal › Article
- 2004
-
Mark
Dialysis-linked complaints and burdens of illness on patient and spouse as predictors of survival in end-stage renal disease patients with home hemodialysis: a 10-year follow-up study
(
- Contribution to journal › Article
- 2003
-
Mark
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
(
- Contribution to journal › Article
-
Mark
High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement
(
- Contribution to journal › Article
- 1999
-
Mark
Recurrent ANCA-associated small vessel vasculitis after transplantation : A pooled analysis
(
- Contribution to journal › Article
-
Mark
C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)- positive vasculitis
(
- Contribution to journal › Article
- 1998
-
Mark
Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody : Technical note
(
- Contribution to journal › Article
- 1997
-
Mark
Autoimmunity in glomerulonephritis; serological diagnosis and clinical outcome with special reference to Wegener´s granulomatosis and microscopic polyangiitis
1997)(
- Thesis › Doctoral thesis (compilation)
- 1993
-
Mark
Increased prevalence of thyroid peroxidase antibodies (TPO-Ab) in women with glomerulonephritis
1993) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 8(5). p.6-402(
- Contribution to journal › Article